

|                    |                       |                 |       |
|--------------------|-----------------------|-----------------|-------|
| <b>POLICY NAME</b> | Myalept (metreleptin) | <b>POLICY #</b> | 2301P |
|--------------------|-----------------------|-----------------|-------|

## Criteria

### Coverage Criteria for the Treatment of Leptin Deficiency, in Addition to Diet, in Patients with Congenital or Acquired Generalized Lipodystrophy

- ☐ Diagnosis of congenital or acquired generalized lipodystrophy (abnormal fat tissue distribution) caused by leptin deficiency
- ☐ Ordered by a specialist enrolled in the Myalept Risk Evaluation and Mitigation Strategy (REMS) Program

### Exclusion Criteria – Any of the following prevents coverage

- ☐ All other indications
- ☐ Not indicated for use in patients with HIV-related lipodystrophy
- ☐ Not indicated for use in patients with metabolic disease, without concurrent evidence of generalized lipodystrophy

### 1 Initial: 12 months

- ☐ Reauthorization: 12 months with documented benefit from therapy CPT Codes HCPCS Codes